- Home
- MGEE vs VKTX Comparison
MGEE vs VKTX Comparison
Compare MGEE & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGEE
- VKTX
- Stock Information
- Founded
- MGEE 1855
- VKTX 2012
- Country
- MGEE United States
- VKTX United States
- Employees
- MGEE N/A
- VKTX N/A
- Industry
- MGEE Electric Utilities: Central
- VKTX Biotechnology: Pharmaceutical Preparations
- Sector
- MGEE Energy
- VKTX Health Care
- Exchange
- MGEE Nasdaq
- VKTX Nasdaq
- Market Cap
- MGEE 3.8B
- VKTX 3.4B
- IPO Year
- MGEE N/A
- VKTX 2015
- Fundamental
- Price
- MGEE $92.19
- VKTX $34.07
- Analyst Decision
- MGEE Sell
- VKTX Strong Buy
- Analyst Count
- MGEE 1
- VKTX 14
- Target Price
- MGEE $74.00
- VKTX $97.29
- AVG Volume (30 Days)
- MGEE 180.9K
- VKTX 4.8M
- Earning Date
- MGEE 03-04-2025
- VKTX 02-05-2025
- Dividend Yield
- MGEE 1.95%
- VKTX N/A
- EPS Growth
- MGEE N/A
- VKTX N/A
- EPS
- MGEE 3.27
- VKTX N/A
- Revenue
- MGEE $653,681,000.00
- VKTX N/A
- Revenue This Year
- MGEE $2.14
- VKTX N/A
- Revenue Next Year
- MGEE $4.75
- VKTX $986.87
- P/E Ratio
- MGEE $28.19
- VKTX N/A
- Revenue Growth
- MGEE N/A
- VKTX N/A
- 52 Week Low
- MGEE $61.94
- VKTX $28.64
- 52 Week High
- MGEE $109.22
- VKTX $99.41
- Technical
- Relative Strength Index (RSI)
- MGEE 55.62
- VKTX 51.41
- Support Level
- MGEE $89.79
- VKTX $28.90
- Resistance Level
- MGEE $91.50
- VKTX $34.37
- Average True Range (ATR)
- MGEE 1.78
- VKTX 2.37
- MACD
- MGEE 0.46
- VKTX 0.66
- Stochastic Oscillator
- MGEE 93.22
- VKTX 70.06
About MGEE MGE Energy Inc
MGE Energy provides electric service to 161,000 customers and natural gas service to 173,000 customers in Madison, Wisconsin, and surrounding areas. Nearly 90% of customers are residential. The company also owns a 3.6% stake in American Transmission Co. MGE owns interests in two coal power plants that earn guaranteed fixed rates of return, contributing about 20% of earnings. MGE's generation mix is 40% coal, 21% renewable energy, 17% natural gas, and third-party purchased power.
About VKTX Viking Therapeutics Inc.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.